131 related articles for article (PubMed ID: 11999465)
1. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.
Kakehi Y; Kamoto T; Shiraishi T; Kato T; Tobisu K; Akakura K; Egawa S; Maeda O; Sumiyoshi Y; Arai Y; Ogawa O
Eur Urol; 2002 Jan; 41(1):47-53. PubMed ID: 11999465
[TBL] [Abstract][Full Text] [Related]
2. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.
Egawa S; Matsumoto K; Suyama K; Iwamura M; Kuwao S; Baba S
Cancer; 1999 Aug; 86(3):463-9. PubMed ID: 10430254
[TBL] [Abstract][Full Text] [Related]
3. Predicting the extent of prostate cancer using the combination of systematic biopsy and serum prostate-specific antigen in Japanese men.
Gohji K; Okamoto M; Takenaka A; Nomi M; Fujii A
BJU Int; 1999 Jan; 83(1):39-42. PubMed ID: 10233449
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
5. PSA doubling time of prostate carcinoma managed with watchful observation alone.
Choo R; DeBoer G; Klotz L; Danjoux C; Morton GC; Rakovitch E; Fleshner N; Bunting P; Kapusta L; Hruby G
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):615-20. PubMed ID: 11395227
[TBL] [Abstract][Full Text] [Related]
6. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
7. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
9. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
10. Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.
Furuya Y; Ohta S; Sato N; Kotake T; Masai M
Int Urol Nephrol; 2002; 33(1):73-6. PubMed ID: 12090344
[TBL] [Abstract][Full Text] [Related]
11. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time among Japanese men in an annual health screening program.
Terai A; Matsui Y; Ichioka K; Ohara H; Terada N; Yoshimura K
Int J Urol; 2004 Oct; 11(10):856-61. PubMed ID: 15479290
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men.
Kakehi Y; Kamoto T; Ogawa O; Kato T; Tobisu K; Akakura K; Egawa S; Usami M; Maeda O; Arai Y; Sumiyoshi Y; Kamiryo Y; Yoshida O
Eur Urol; 2000 May; 37(5):552-8. PubMed ID: 10765093
[TBL] [Abstract][Full Text] [Related]
15. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
16. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
17. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy.
Liebross RH; Pollack A; Lankford SP; von Eschenbach AC; Zagars GK
Urology; 1998 Oct; 52(4):647-52. PubMed ID: 9763087
[TBL] [Abstract][Full Text] [Related]
18. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
19. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
20. [PSA-doubling time immediately before the diagnosis of prostate cancer].
Nakata S; Hasumi M; Suzuki T; Sato J; Imai K; Yamanaka H; Shimizu T
Hinyokika Kiyo; 1998 Feb; 44(2):81-4. PubMed ID: 9546125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
